Breast Cancer Vaccines Based on Dendritic Cells and the Chemokines
Abstract
The major objective of this project is to establish a new modality for the treatment of breast cancer that employs the combination of chemokines with breast tumor-pulsed dendritic cells to both recruit and/or concentrate from the periphery low frequency immune reactive T cells as well as to potently stimulate these effector cells once localized at the vaccination site. During the fourth year of this project, studies were focused on four major areas specified either in the Statement of Work or in response to issues raised in the original Peer Review Panel Report: (1) to complete in vitro optimization of human DC generation and function; (2) to identify the most promising chemokine to focus our efforts; (3) to identify the most efficient delivery of a chemokine gene; and (4) to test the vaccine strategy in a relevant breast tumor model in mice. These areas have all been successful and have resulted in eight additional publications (totaling 17 publications to date for the project), the awarding of a new spin-off NCI/NIH R01 grant, and the initiation of a phase II clinical trial in advanced breast cancer patients. During the course of our studies related to the Technical Objectives, we made the important discovery that SLC can significantly inhibit the growth of breast tumor in mice. We successfully constructed a recombinant adenovirus vector containing the SLC gene, which can transduce dendritic cells at high efficiency for use in our cancer vaccine strategy. The data and the appended publications provided in this fourth annual report show our overall accomplishments and productivity in this DoD funded research project.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2000
- Accession Number
- ADA385673
Entities
People
- James Mulé
Organizations
- University of Michigan